Share Price and Basic Stock Data
Last Updated: November 8, 2025, 5:48 am
| PEG Ratio | 4.03 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Astrazeneca Pharma India Ltd operates within the pharmaceuticals industry, with a current share price of ₹9,316 and a market capitalization of ₹23,289 Cr. The company reported a revenue from operations of ₹1,003 Cr for the fiscal year ending March 2023, which increased to ₹1,296 Cr for the fiscal year ending March 2024, and further rose to ₹1,716 Cr for the fiscal year ending March 2025. This consistent growth in sales reflects a robust demand for its pharmaceutical products. The quarterly sales figures also indicate a positive trajectory, with sales rising from ₹232 Cr in June 2022 to ₹311 Cr by September 2023. Astrazeneca’s revenue from operations per share stood at ₹686.52 for the fiscal year ending March 2025, up from ₹518.21 the previous year. This performance underscores the company’s ability to expand its market presence and capitalize on growth opportunities in the pharmaceutical sector.
Profitability and Efficiency Metrics
The profitability of Astrazeneca Pharma India Ltd is highlighted by its reported net profit of ₹183 Cr for the trailing twelve months (TTM), reflecting a net profit margin of 6.74% for the fiscal year ending March 2025. The operating profit margin (OPM) stood at 15% for the current fiscal year, with a notable peak of 23% in June 2023, demonstrating effective cost management and operational efficiency. The company recorded a return on equity (ROE) of 23.6% and a return on capital employed (ROCE) of 33.4%, both significantly higher than many industry peers, indicating effective utilization of equity and capital. The interest coverage ratio (ICR) reported at 201.78x further illustrates the company’s strong ability to meet its interest obligations, suggesting financial stability. However, the fluctuations in OPM, particularly a drop to 5% in December 2023, may raise concerns about profitability consistency.
Balance Sheet Strength and Financial Ratios
Astrazeneca Pharma India Ltd maintains a healthy balance sheet, with total assets reported at ₹1,518 Cr and total liabilities at ₹1,518 Cr for the fiscal year ending March 2025. The company’s equity capital remains stable at ₹5 Cr, while reserves have increased to ₹765 Cr, indicating a solid foundation for growth. Borrowings are minimal at ₹36 Cr, showcasing low leverage and reducing financial risk. The price-to-book value (P/BV) ratio stood at 27.93x, significantly above the sector average, which may indicate overvaluation or high investor expectations. The current ratio is reported at 1.91, exceeding the typical benchmark of 1.5, suggesting adequate short-term liquidity. The enterprise value (EV) to net operating revenue ratio of 12.22x indicates premium valuation, reflecting investor confidence in the company’s future prospects, although this may also present a risk if growth expectations are not met.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Astrazeneca Pharma India Ltd reveals a strong promoter holding of 75%, which underscores management confidence in the company’s direction. Foreign institutional investors (FIIs) have increased their stake from 2.49% in September 2022 to 3.03% by June 2025, reflecting growing interest from overseas investors. Domestic institutional investors (DIIs) also hold a significant 4.55% stake as of June 2025, indicating institutional confidence in the company’s performance. The total number of shareholders stood at 34,378, a recovery from a low of 27,169 in June 2024, suggesting renewed investor interest. However, the public holding has seen a decline from 21.19% in September 2022 to 17.41% in June 2025, which may raise concerns about liquidity and market participation.
Outlook, Risks, and Final Insight
Astrazeneca Pharma India Ltd’s outlook appears positive, driven by strong revenue growth and solid profitability metrics, coupled with a robust balance sheet. However, the company faces risks associated with fluctuating operating profit margins and a high P/BV ratio, which may affect investor sentiment if growth slows. Furthermore, the decline in public shareholding could impact liquidity, making it essential for the company to engage with retail investors. The pharmaceutical sector is also subject to regulatory changes and competitive pressures, which could hinder growth. Overall, maintaining operational efficiency, managing costs, and enhancing shareholder communication will be critical in sustaining growth and investor confidence in the future.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Astrazeneca Pharma India Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 137 Cr. | 109 | 247/84.3 | 31.1 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.63 Cr. | 1.90 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,906 Cr. | 450 | 479/192 | 110 | 22.8 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.1 Cr. | 46.0 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 36.9 Cr. | 25.2 | 29.1/17.0 | 38.5 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,608.79 Cr | 1,177.38 | 55.81 | 198.49 | 0.34% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 232 | 236 | 250 | 285 | 295 | 311 | 306 | 383 | 388 | 408 | 440 | 480 | 526 |
| Expenses | 204 | 195 | 213 | 225 | 228 | 258 | 291 | 334 | 349 | 355 | 363 | 394 | 445 |
| Operating Profit | 28 | 41 | 37 | 60 | 67 | 53 | 15 | 49 | 38 | 53 | 77 | 86 | 81 |
| OPM % | 12% | 17% | 15% | 21% | 23% | 17% | 5% | 13% | 10% | 13% | 17% | 18% | 15% |
| Other Income | 4 | 7 | 7 | -32 | 8 | 25 | 10 | 9 | -49 | 8 | -26 | 10 | 11 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 1 | -0 | 0 | 0 | 0 | 1 | 1 |
| Depreciation | 5 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 9 | 9 | 18 | 17 |
| Profit before tax | 27 | 44 | 39 | 23 | 71 | 73 | 20 | 54 | -15 | 51 | 42 | 78 | 75 |
| Tax % | 26% | 26% | 26% | 26% | 25% | 29% | 23% | 27% | -22% | 25% | 27% | 26% | 25% |
| Net Profit | 20 | 33 | 29 | 17 | 54 | 52 | 16 | 39 | -12 | 38 | 31 | 58 | 56 |
| EPS in Rs | 8.06 | 13.02 | 11.72 | 6.91 | 21.54 | 20.95 | 6.32 | 15.79 | -4.72 | 15.37 | 12.34 | 23.30 | 22.33 |
Last Updated: August 20, 2025, 1:25 pm
Below is a detailed analysis of the quarterly data for Astrazeneca Pharma India Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 526.00 Cr.. The value appears strong and on an upward trend. It has increased from 480.00 Cr. (Mar 2025) to 526.00 Cr., marking an increase of 46.00 Cr..
- For Expenses, as of Jun 2025, the value is 445.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 394.00 Cr. (Mar 2025) to 445.00 Cr., marking an increase of 51.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 81.00 Cr.. The value appears to be declining and may need further review. It has decreased from 86.00 Cr. (Mar 2025) to 81.00 Cr., marking a decrease of 5.00 Cr..
- For OPM %, as of Jun 2025, the value is 15.00%. The value appears to be declining and may need further review. It has decreased from 18.00% (Mar 2025) to 15.00%, marking a decrease of 3.00%.
- For Other Income, as of Jun 2025, the value is 11.00 Cr.. The value appears strong and on an upward trend. It has increased from 10.00 Cr. (Mar 2025) to 11.00 Cr., marking an increase of 1.00 Cr..
- For Interest, as of Jun 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.00 Cr..
- For Depreciation, as of Jun 2025, the value is 17.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 18.00 Cr. (Mar 2025) to 17.00 Cr., marking a decrease of 1.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 75.00 Cr.. The value appears to be declining and may need further review. It has decreased from 78.00 Cr. (Mar 2025) to 75.00 Cr., marking a decrease of 3.00 Cr..
- For Tax %, as of Jun 2025, the value is 25.00%. The value appears to be improving (decreasing) as expected. It has decreased from 26.00% (Mar 2025) to 25.00%, marking a decrease of 1.00%.
- For Net Profit, as of Jun 2025, the value is 56.00 Cr.. The value appears to be declining and may need further review. It has decreased from 58.00 Cr. (Mar 2025) to 56.00 Cr., marking a decrease of 2.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 22.33. The value appears to be declining and may need further review. It has decreased from 23.30 (Mar 2025) to 22.33, marking a decrease of 0.97.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: August 22, 2025, 5:25 pm
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 474 | 517 | 564 | 544 | 571 | 728 | 832 | 814 | 806 | 1,003 | 1,296 | 1,716 | 1,855 |
| Expenses | 487 | 528 | 547 | 506 | 525 | 657 | 711 | 678 | 719 | 838 | 1,111 | 1,462 | 1,558 |
| Operating Profit | -13 | -11 | 16 | 37 | 46 | 71 | 121 | 135 | 86 | 165 | 184 | 254 | 297 |
| OPM % | -3% | -2% | 3% | 7% | 8% | 10% | 15% | 17% | 11% | 16% | 14% | 15% | 16% |
| Other Income | 23 | 6 | 7 | 14 | 12 | 16 | 13 | 13 | 15 | -14 | 51 | -56 | 4 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 2 |
| Depreciation | 10 | 15 | 17 | 16 | 15 | 15 | 19 | 20 | 17 | 16 | 15 | 40 | 53 |
| Profit before tax | 0 | -21 | 6 | 36 | 44 | 73 | 114 | 127 | 83 | 134 | 220 | 156 | 246 |
| Tax % | 0% | 9% | 44% | 41% | 25% | 37% | 27% | 26% | 26% | 26% | 26% | ||
| Net Profit | -1 | -21 | 5 | 20 | 26 | 54 | 72 | 93 | 62 | 99 | 162 | 116 | 183 |
| EPS in Rs | -0.20 | -8.34 | 2.10 | 8.02 | 10.36 | 21.78 | 28.88 | 37.32 | 24.64 | 39.72 | 64.60 | 46.30 | 73.34 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 3% | 5% | 41% | 40% | 37% | 69% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -2000.00% | 123.81% | 300.00% | 30.00% | 107.69% | 33.33% | 29.17% | -33.33% | 59.68% | 63.64% | -28.40% |
| Change in YoY Net Profit Growth (%) | 0.00% | 2123.81% | 176.19% | -270.00% | 77.69% | -74.36% | -4.17% | -62.50% | 93.01% | 3.96% | -92.03% |
Astrazeneca Pharma India Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 16% |
| 3 Years: | 29% |
| TTM: | 34% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 26% |
| 5 Years: | 19% |
| 3 Years: | 43% |
| TTM: | 61% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 23% |
| 5 Years: | 19% |
| 3 Years: | 44% |
| 1 Year: | 32% |
| Return on Equity | |
|---|---|
| 10 Years: | 19% |
| 5 Years: | 21% |
| 3 Years: | 23% |
| Last Year: | 24% |
Last Updated: September 4, 2025, 11:55 pm
Balance Sheet
Last Updated: June 16, 2025, 12:27 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Reserves | 167 | 146 | 151 | 218 | 242 | 296 | 359 | 451 | 506 | 584 | 707 | 765 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 12 | 9 | 7 | 5 | 36 |
| Other Liabilities | 244 | 261 | 247 | 193 | 214 | 261 | 330 | 306 | 337 | 389 | 362 | 712 |
| Total Liabilities | 416 | 412 | 403 | 415 | 461 | 562 | 706 | 775 | 857 | 985 | 1,078 | 1,518 |
| Fixed Assets | 94 | 101 | 97 | 87 | 75 | 75 | 72 | 81 | 74 | 69 | 67 | 64 |
| CWIP | 9 | 12 | 6 | 5 | 4 | 7 | 24 | 4 | 2 | 1 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 312 | 298 | 299 | 324 | 382 | 480 | 611 | 690 | 780 | 915 | 1,011 | 1,454 |
| Total Assets | 416 | 412 | 403 | 415 | 461 | 562 | 706 | 775 | 857 | 985 | 1,078 | 1,518 |
Below is a detailed analysis of the balance sheet data for Astrazeneca Pharma India Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 5.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 5.00 Cr..
- For Reserves, as of Mar 2025, the value is 765.00 Cr.. The value appears strong and on an upward trend. It has increased from 707.00 Cr. (Mar 2024) to 765.00 Cr., marking an increase of 58.00 Cr..
- For Borrowings, as of Mar 2025, the value is 36.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 5.00 Cr. (Mar 2024) to 36.00 Cr., marking an increase of 31.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 712.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 362.00 Cr. (Mar 2024) to 712.00 Cr., marking an increase of 350.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 1,518.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,078.00 Cr. (Mar 2024) to 1,518.00 Cr., marking an increase of 440.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 64.00 Cr.. The value appears to be declining and may need further review. It has decreased from 67.00 Cr. (Mar 2024) to 64.00 Cr., marking a decrease of 3.00 Cr..
- For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Other Assets, as of Mar 2025, the value is 1,454.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,011.00 Cr. (Mar 2024) to 1,454.00 Cr., marking an increase of 443.00 Cr..
- For Total Assets, as of Mar 2025, the value is 1,518.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,078.00 Cr. (Mar 2024) to 1,518.00 Cr., marking an increase of 440.00 Cr..
Notably, the Reserves (765.00 Cr.) exceed the Borrowings (36.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -13.00 | -11.00 | 16.00 | 37.00 | 46.00 | 71.00 | 109.00 | 123.00 | 77.00 | 158.00 | 179.00 | 218.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 41 | 30 | 54 | 29 | 35 | 40 | 37 | 38 | 39 | 39 | 43 | 39 |
| Inventory Days | 210 | 157 | 141 | 121 | 229 | 186 | 197 | 198 | 164 | 193 | 140 | 208 |
| Days Payable | 241 | 203 | 174 | 184 | 257 | 266 | 251 | 221 | 223 | 231 | 121 | 173 |
| Cash Conversion Cycle | 10 | -16 | 21 | -34 | 7 | -39 | -17 | 15 | -20 | 1 | 62 | 74 |
| Working Capital Days | -45 | -15 | -28 | -36 | -8 | -14 | -16 | -17 | -34 | -18 | 20 | 22 |
| ROCE % | -12% | -13% | 4% | 15% | 19% | 27% | 34% | 30% | 16% | 31% | 31% | 33% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Nippon India Small Cap Fund | 645,850 | 0.93 | 427.33 | 645,850 | 2025-04-22 17:25:41 | 0% |
| Nippon India Pharma Fund | 11,561 | 0.11 | 7.65 | 11,561 | 2025-04-22 17:25:41 | 0% |
| ICICI Prudential MNC Fund | 5,667 | 0.24 | 3.75 | 5,667 | 2025-04-22 17:25:41 | 0% |
| ICICI Prudential S&P BSE 500 ETF | 72 | 0.03 | 0.05 | 72 | 2025-04-22 17:25:41 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Basic EPS (Rs.) | 46.30 | 64.60 | 39.70 | 24.60 | 37.30 |
| Diluted EPS (Rs.) | 46.30 | 64.60 | 39.70 | 24.60 | 37.30 |
| Cash EPS (Rs.) | 62.29 | 70.58 | 46.22 | 31.42 | 45.37 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 308.14 | 284.77 | 235.48 | 204.56 | 182.47 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 308.14 | 284.77 | 235.48 | 204.56 | 182.47 |
| Dividend / Share (Rs.) | 32.00 | 24.00 | 16.00 | 10.00 | 2.00 |
| Revenue From Operations / Share (Rs.) | 686.52 | 518.21 | 401.19 | 322.24 | 325.42 |
| PBDIT / Share (Rs.) | 117.84 | 87.70 | 76.49 | 40.38 | 59.32 |
| PBIT / Share (Rs.) | 101.84 | 81.72 | 69.98 | 33.60 | 51.27 |
| PBT / Share (Rs.) | 62.54 | 87.82 | 53.64 | 33.22 | 50.84 |
| Net Profit / Share (Rs.) | 46.30 | 64.60 | 39.72 | 24.64 | 37.32 |
| PBDIT Margin (%) | 17.16 | 16.92 | 19.06 | 12.52 | 18.22 |
| PBIT Margin (%) | 14.83 | 15.77 | 17.44 | 10.42 | 15.75 |
| PBT Margin (%) | 9.11 | 16.94 | 13.37 | 10.30 | 15.62 |
| Net Profit Margin (%) | 6.74 | 12.46 | 9.89 | 7.64 | 11.46 |
| Return on Networth / Equity (%) | 15.02 | 22.68 | 16.86 | 12.04 | 20.45 |
| Return on Capital Employeed (%) | 31.23 | 28.34 | 29.11 | 16.03 | 27.20 |
| Return On Assets (%) | 7.62 | 14.98 | 10.08 | 7.19 | 12.04 |
| Asset Turnover Ratio (%) | 1.32 | 1.26 | 1.09 | 0.98 | 1.10 |
| Current Ratio (X) | 1.91 | 2.61 | 2.18 | 2.12 | 2.04 |
| Quick Ratio (X) | 1.13 | 1.97 | 1.68 | 1.70 | 1.51 |
| Inventory Turnover Ratio (X) | 4.42 | 0.61 | 0.51 | 0.59 | 0.59 |
| Dividend Payout Ratio (NP) (%) | 51.84 | 24.76 | 20.14 | 8.11 | 5.35 |
| Dividend Payout Ratio (CP) (%) | 38.52 | 22.66 | 17.30 | 6.36 | 4.40 |
| Earning Retention Ratio (%) | 48.16 | 75.24 | 79.86 | 91.89 | 94.65 |
| Cash Earning Retention Ratio (%) | 61.48 | 77.34 | 82.70 | 93.64 | 95.60 |
| Interest Coverage Ratio (X) | 201.78 | 182.71 | 303.52 | 106.25 | 136.06 |
| Interest Coverage Ratio (Post Tax) (X) | 146.57 | 121.90 | 222.46 | 65.84 | 86.60 |
| Enterprise Value (Cr.) | 20979.18 | 12795.16 | 7617.77 | 5940.17 | 7173.15 |
| EV / Net Operating Revenue (X) | 12.22 | 9.88 | 7.60 | 7.37 | 8.82 |
| EV / EBITDA (X) | 71.21 | 58.36 | 39.84 | 58.85 | 48.37 |
| MarketCap / Net Operating Revenue (X) | 12.54 | 10.27 | 8.09 | 7.93 | 9.25 |
| Retention Ratios (%) | 48.15 | 75.23 | 79.85 | 91.88 | 94.64 |
| Price / BV (X) | 27.93 | 18.68 | 13.79 | 12.49 | 16.50 |
| Price / Net Operating Revenue (X) | 12.54 | 10.27 | 8.09 | 7.93 | 9.25 |
| EarningsYield | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
After reviewing the key financial ratios for Astrazeneca Pharma India Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 46.30. This value is within the healthy range. It has decreased from 64.60 (Mar 24) to 46.30, marking a decrease of 18.30.
- For Diluted EPS (Rs.), as of Mar 25, the value is 46.30. This value is within the healthy range. It has decreased from 64.60 (Mar 24) to 46.30, marking a decrease of 18.30.
- For Cash EPS (Rs.), as of Mar 25, the value is 62.29. This value is within the healthy range. It has decreased from 70.58 (Mar 24) to 62.29, marking a decrease of 8.29.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 308.14. It has increased from 284.77 (Mar 24) to 308.14, marking an increase of 23.37.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 308.14. It has increased from 284.77 (Mar 24) to 308.14, marking an increase of 23.37.
- For Dividend / Share (Rs.), as of Mar 25, the value is 32.00. This value exceeds the healthy maximum of 3. It has increased from 24.00 (Mar 24) to 32.00, marking an increase of 8.00.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 686.52. It has increased from 518.21 (Mar 24) to 686.52, marking an increase of 168.31.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 117.84. This value is within the healthy range. It has increased from 87.70 (Mar 24) to 117.84, marking an increase of 30.14.
- For PBIT / Share (Rs.), as of Mar 25, the value is 101.84. This value is within the healthy range. It has increased from 81.72 (Mar 24) to 101.84, marking an increase of 20.12.
- For PBT / Share (Rs.), as of Mar 25, the value is 62.54. This value is within the healthy range. It has decreased from 87.82 (Mar 24) to 62.54, marking a decrease of 25.28.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 46.30. This value is within the healthy range. It has decreased from 64.60 (Mar 24) to 46.30, marking a decrease of 18.30.
- For PBDIT Margin (%), as of Mar 25, the value is 17.16. This value is within the healthy range. It has increased from 16.92 (Mar 24) to 17.16, marking an increase of 0.24.
- For PBIT Margin (%), as of Mar 25, the value is 14.83. This value is within the healthy range. It has decreased from 15.77 (Mar 24) to 14.83, marking a decrease of 0.94.
- For PBT Margin (%), as of Mar 25, the value is 9.11. This value is below the healthy minimum of 10. It has decreased from 16.94 (Mar 24) to 9.11, marking a decrease of 7.83.
- For Net Profit Margin (%), as of Mar 25, the value is 6.74. This value is within the healthy range. It has decreased from 12.46 (Mar 24) to 6.74, marking a decrease of 5.72.
- For Return on Networth / Equity (%), as of Mar 25, the value is 15.02. This value is within the healthy range. It has decreased from 22.68 (Mar 24) to 15.02, marking a decrease of 7.66.
- For Return on Capital Employeed (%), as of Mar 25, the value is 31.23. This value is within the healthy range. It has increased from 28.34 (Mar 24) to 31.23, marking an increase of 2.89.
- For Return On Assets (%), as of Mar 25, the value is 7.62. This value is within the healthy range. It has decreased from 14.98 (Mar 24) to 7.62, marking a decrease of 7.36.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.32. It has increased from 1.26 (Mar 24) to 1.32, marking an increase of 0.06.
- For Current Ratio (X), as of Mar 25, the value is 1.91. This value is within the healthy range. It has decreased from 2.61 (Mar 24) to 1.91, marking a decrease of 0.70.
- For Quick Ratio (X), as of Mar 25, the value is 1.13. This value is within the healthy range. It has decreased from 1.97 (Mar 24) to 1.13, marking a decrease of 0.84.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.42. This value is within the healthy range. It has increased from 0.61 (Mar 24) to 4.42, marking an increase of 3.81.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 51.84. This value exceeds the healthy maximum of 50. It has increased from 24.76 (Mar 24) to 51.84, marking an increase of 27.08.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 38.52. This value is within the healthy range. It has increased from 22.66 (Mar 24) to 38.52, marking an increase of 15.86.
- For Earning Retention Ratio (%), as of Mar 25, the value is 48.16. This value is within the healthy range. It has decreased from 75.24 (Mar 24) to 48.16, marking a decrease of 27.08.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 61.48. This value is within the healthy range. It has decreased from 77.34 (Mar 24) to 61.48, marking a decrease of 15.86.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 201.78. This value is within the healthy range. It has increased from 182.71 (Mar 24) to 201.78, marking an increase of 19.07.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 146.57. This value is within the healthy range. It has increased from 121.90 (Mar 24) to 146.57, marking an increase of 24.67.
- For Enterprise Value (Cr.), as of Mar 25, the value is 20,979.18. It has increased from 12,795.16 (Mar 24) to 20,979.18, marking an increase of 8,184.02.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 12.22. This value exceeds the healthy maximum of 3. It has increased from 9.88 (Mar 24) to 12.22, marking an increase of 2.34.
- For EV / EBITDA (X), as of Mar 25, the value is 71.21. This value exceeds the healthy maximum of 15. It has increased from 58.36 (Mar 24) to 71.21, marking an increase of 12.85.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 12.54. This value exceeds the healthy maximum of 3. It has increased from 10.27 (Mar 24) to 12.54, marking an increase of 2.27.
- For Retention Ratios (%), as of Mar 25, the value is 48.15. This value is within the healthy range. It has decreased from 75.23 (Mar 24) to 48.15, marking a decrease of 27.08.
- For Price / BV (X), as of Mar 25, the value is 27.93. This value exceeds the healthy maximum of 3. It has increased from 18.68 (Mar 24) to 27.93, marking an increase of 9.25.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 12.54. This value exceeds the healthy maximum of 3. It has increased from 10.27 (Mar 24) to 12.54, marking an increase of 2.27.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Astrazeneca Pharma India Ltd:
- Net Profit Margin: 6.74%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 31.23% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 15.02% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 146.57
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.13
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 98.2 (Industry average Stock P/E: 55.81)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 6.74%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Block N1, 12th Floor, Bengaluru Karnataka 560045 | comp.secy@astrazeneca.com http://www.astrazeneca.com/india |
| Management | |
|---|---|
| Name | Position Held |
| Ms. Shilpa Divekar Nirula | Chairperson & Independent Director |
| Mr. Praveen Rao Akkinepally | Managing Director |
| Ms. Bhavana Agrawal | Executive Director |
| Ms. Sylvia Lorena Varela Ramon | Non Executive Director |
| Ms. Hooi Bien Chuah | Non Executive Director |
| Mr. Jesus Javier Diaz-Ropero Esteso | Non Executive Director |
| Ms. Revathy Ashok | Independent Director |
| Ms. Monica Widhani | Independent Director |
FAQ
What is the intrinsic value of Astrazeneca Pharma India Ltd?
Astrazeneca Pharma India Ltd's intrinsic value (as of 08 November 2025) is 5953.62 which is 34.42% lower the current market price of 9,078.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 22,694 Cr. market cap, FY2025-2026 high/low of 10,691/6,220, reserves of ₹765 Cr, and liabilities of 1,518 Cr.
What is the Market Cap of Astrazeneca Pharma India Ltd?
The Market Cap of Astrazeneca Pharma India Ltd is 22,694 Cr..
What is the current Stock Price of Astrazeneca Pharma India Ltd as on 08 November 2025?
The current stock price of Astrazeneca Pharma India Ltd as on 08 November 2025 is 9,078.
What is the High / Low of Astrazeneca Pharma India Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Astrazeneca Pharma India Ltd stocks is 10,691/6,220.
What is the Stock P/E of Astrazeneca Pharma India Ltd?
The Stock P/E of Astrazeneca Pharma India Ltd is 98.2.
What is the Book Value of Astrazeneca Pharma India Ltd?
The Book Value of Astrazeneca Pharma India Ltd is 320.
What is the Dividend Yield of Astrazeneca Pharma India Ltd?
The Dividend Yield of Astrazeneca Pharma India Ltd is 0.35 %.
What is the ROCE of Astrazeneca Pharma India Ltd?
The ROCE of Astrazeneca Pharma India Ltd is 33.4 %.
What is the ROE of Astrazeneca Pharma India Ltd?
The ROE of Astrazeneca Pharma India Ltd is 23.6 %.
What is the Face Value of Astrazeneca Pharma India Ltd?
The Face Value of Astrazeneca Pharma India Ltd is 2.00.